[{"id":"fd69b3ec-1305-4dd1-87d3-4b0c8f4a1b9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661384","created_at":"2025-06-07T14:44:26.057Z","updated_at":"2025-06-07T14:44:26.057Z","phase":"Phase 1","brief_title":"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma","source_id_and_acronym":"NCT04661384","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":"","alterations":" ","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/17/2025","primary_completion_date":" 11/17/2025","study_txt":" Completion: 11/17/2025","study_completion_date":" 11/17/2025","last_update_posted":"2025-06-03"},{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"a3758200-2675-4c3a-9e8c-8a19c87396ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04230265","created_at":"2023-08-14T10:11:02.629Z","updated_at":"2025-02-25T15:43:50.590Z","phase":"Phase 1","brief_title":"Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT04230265","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-11"},{"id":"36e68fbc-8506-4572-acf5-3e86f4ea808b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949125","created_at":"2023-08-14T10:11:12.134Z","updated_at":"2025-02-25T15:28:11.863Z","phase":"Phase 1","brief_title":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT05949125","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-201"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-10"},{"id":"1d8370c0-0ea2-467e-9dcf-8b1993e03ba2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04003649","created_at":"2025-02-26T07:16:30.395Z","updated_at":"2025-02-26T07:16:30.395Z","phase":"Phase 1","brief_title":"IL13Ra2-CAR T Cells with or Without Nivolumab and Ipilimumab in Treating Patients with GBM","source_id_and_acronym":"NCT04003649","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL13RA2","pipe":"","alterations":" ","tags":["IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 03/26/2025","primary_completion_date":" 03/26/2025","study_txt":" Completion: 03/26/2025","study_completion_date":" 03/26/2025","last_update_posted":"2024-10-10"},{"id":"3052bc57-4b7f-4d7b-af0a-54caa20088ad","acronym":"BAH244","url":"https://clinicaltrials.gov/study/NCT06420063","created_at":"2024-05-25T04:14:21.722Z","updated_at":"2024-07-02T16:35:01.962Z","phase":"Phase 1/2","brief_title":"Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML","source_id_and_acronym":"NCT06420063 - BAH244","lead_sponsor":"Essen Biotech","biomarkers":" CD5 • CD7","pipe":"","alterations":" ","tags":["CD5 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/10/2024","start_date":" 10/10/2024","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 12/28/2026","study_completion_date":" 12/28/2026","last_update_posted":"2024-05-22"},{"id":"80508af6-7ecc-4d80-9db9-bae1a12b6cde","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168423","created_at":"2021-12-23T16:53:41.350Z","updated_at":"2024-07-02T16:35:20.694Z","phase":"Phase 1","brief_title":"CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM","source_id_and_acronym":"NCT05168423","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR wild-type • IDH wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 12/19/2039","study_completion_date":" 12/19/2039","last_update_posted":"2024-02-06"},{"id":"0a2db8ff-cbd1-468b-a91f-239d3b97766f","acronym":"AMELI-01","url":"https://clinicaltrials.gov/study/NCT03190278","created_at":"2023-08-14T10:10:57.638Z","updated_at":"2024-07-02T16:35:20.952Z","phase":"Phase 1","brief_title":"Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03190278 - AMELI-01","lead_sponsor":"Cellectis S.A.","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCART123"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/19/2017","start_date":" 06/19/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-05"},{"id":"9f422a88-402d-4776-a63e-899f8ce422df","acronym":"NCI-2014-01147","url":"https://clinicaltrials.gov/study/NCT02159495","created_at":"2021-01-18T10:03:02.202Z","updated_at":"2024-07-02T16:35:21.732Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT02159495 - NCI-2014-01147","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["FLT3 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-01-30"},{"id":"50192133-c8e8-4b6f-9edf-895d64f162f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05995041","created_at":"2023-08-16T16:08:27.797Z","updated_at":"2024-07-02T16:35:33.734Z","phase":"Phase 1","brief_title":"Universal CAR-T Cells Targeting AML","source_id_and_acronym":"NCT05995041","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD38 • CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-12"},{"id":"f871fea9-e2b8-4a4c-97ed-93bea378ea0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04510051","created_at":"2021-01-18T21:37:11.984Z","updated_at":"2024-07-02T16:35:34.277Z","phase":"Phase 1","brief_title":"CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children","source_id_and_acronym":"NCT04510051","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":" | ","alterations":" CD123 expression","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 08/24/2024","study_completion_date":" 08/24/2024","last_update_posted":"2023-10-09"},{"id":"23fe5699-b91c-473a-b6f8-99a276ffb074","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272125","created_at":"2021-01-18T20:45:10.451Z","updated_at":"2024-07-02T16:35:50.369Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04272125","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"2f6c09fe-648a-43a4-b8de-c7035dd17c75","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265963","created_at":"2021-01-18T20:43:42.945Z","updated_at":"2024-07-02T16:35:50.304Z","phase":"Phase 1/2","brief_title":"CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04265963","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"4cd00ace-eb77-4eb4-8c29-3d41b9d5e4fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05513612","created_at":"2022-08-24T21:07:38.118Z","updated_at":"2024-07-02T16:35:54.501Z","phase":"Phase 1","brief_title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","source_id_and_acronym":"NCT05513612","lead_sponsor":"Shanghai Pudong Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Autologous CAR-T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-03-01"},{"id":"01bdc6f6-0410-48c7-88ae-60f097419d24","acronym":"","url":"https://clinicaltrials.gov/study/NCT03585517","created_at":"2023-08-14T10:10:59.415Z","updated_at":"2024-07-02T16:35:57.376Z","phase":"Phase 1","brief_title":"Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)","source_id_and_acronym":"NCT03585517","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • IM23"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/21/2018","start_date":" 07/21/2018","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2023-01-19"},{"id":"4af37b5e-53c0-463d-aa29-d4176aa0cac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04637503","created_at":"2021-01-19T20:37:37.669Z","updated_at":"2024-07-02T16:36:38.465Z","phase":"Phase 1/2","brief_title":"4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma","source_id_and_acronym":"NCT04637503","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T • GD2, PSMA and CD276 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-11-19"},{"id":"c680c5d8-4f65-49d8-aa7d-65b4bcfd55e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04106076","created_at":"2023-03-04T19:03:31.381Z","updated_at":"2024-07-02T16:36:43.310Z","phase":"Phase 1","brief_title":"Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT04106076","lead_sponsor":"Cellectis S.A.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCART123"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/05/2019","primary_completion_date":" 12/05/2019","study_txt":" Completion: 12/05/2019","study_completion_date":" 12/05/2019","last_update_posted":"2020-07-14"},{"id":"0f73e762-cc4d-4587-b6bb-5b28a5196876","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430530","created_at":"2021-01-18T21:20:13.869Z","updated_at":"2024-07-02T16:36:44.211Z","phase":"Phase 1/2","brief_title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","source_id_and_acronym":"NCT04430530","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CD123 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CD123 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"8ecd0d5a-4acf-4233-aeb0-ac0394f32647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430595","created_at":"2021-01-18T21:20:15.327Z","updated_at":"2024-07-02T16:36:44.254Z","phase":"Phase 1/2","brief_title":"Multi-4SCAR-T Therapy Targeting Breast Cancer","source_id_and_acronym":"NCT04430595","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • CD44 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CD44 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"0c9e63e6-e013-4d60-9884-43f80b3ef7f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04016129","created_at":"2021-01-18T19:43:30.822Z","updated_at":"2024-07-02T16:36:55.506Z","phase":"Phase 1/2","brief_title":"CAR-T Immunotherapy Targeting CD19- ALL","source_id_and_acronym":"NCT04016129","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2019-09-19"},{"id":"302a874f-6617-4986-8f96-30d12232b833","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125577","created_at":"2021-01-18T15:23:58.289Z","updated_at":"2024-07-02T16:36:55.542Z","phase":"Phase 1/2","brief_title":"Combination CAR-T Cell Therapy Targeting Hematological Malignancies","source_id_and_acronym":"NCT03125577","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD19 • TNFRSF8 • CD38 • CD123 • CD22 • CD70 • IL3RA","pipe":" | ","alterations":" TNFRSF8 expression • CD20 expression • CD19 expression","tags":["CD20 • CD19 • TNFRSF8 • CD38 • CD123 • CD22 • CD70 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • CD20 expression • CD19 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 07/31/2019","primary_completion_date":" 07/31/2019","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2019-09-19"},{"id":"d2dd03bc-0fae-46dc-868b-5c48fa14ca32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04010877","created_at":"2021-01-18T19:42:18.741Z","updated_at":"2024-07-02T16:36:55.454Z","phase":"Phase 1/2","brief_title":"Multiple CAR-T Cell Therapy Targeting AML","source_id_and_acronym":"NCT04010877","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2019-09-19"},{"id":"78e1680d-703f-4e5f-957a-df94de13cc39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04014881","created_at":"2021-01-18T19:43:13.211Z","updated_at":"2024-07-02T16:36:57.207Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.","source_id_and_acronym":"NCT04014881","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD123 CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/06/2019","start_date":" 07/06/2019","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-08-07"}]